Drugs online research references









  • Effect of acute or repeated stress on behavior and brain norepinephrine system in Wistar-Kyoto (WKY) rats.
  • Reduced levels of norepinephrine transporters in the locus coeruleus in major depression.
  • In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.
  • Atypical antidepressants inhibit depolarization-induced calcium uptake in rat hippocampus synaptosomes.
  • Determination of p-trifluoromethylphenol, a metabolite of fluoxetine, in tissues and body fluids using an electron-capture gas chromatographic procedure.
  • Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
  • Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities.
  • Enhancement of the anticonvulsant effect of fluoxetine following blockade of 5-HT1A receptors.
  • Sensitive and rapid method for the simultaneous quantification of five antidepressants with their respective metabolites in plasma using high-performance liquid chromatography with diode-array detection.
  • Determination of fluoxetine in human plasma using reserved phase HPLC.
  • Rx drugs
  • Combined naloxone and fluoxetine on deprivation-induced binge eating of palatable foods in rats.
  • Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
  • Guinea pig pancreatic neurons: morphology, neurochemistry, electrical properties, and response to 5-HT.
  • Feedback stimulation of somatodendritic serotonin release: a 5-HT3 receptor-mediated effect in the raphe nuclei of the rat.
  • Interactions between promazine and antidepressants at the level of cellular distribution.
  • Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine.
  • Interindividual differences in active and passive behaviors in the forced-swimming test: implications for animal models of psychopathology.
  • Breast enlargement during chronic antidepressant therapy.
  • Release and uptake rates of 5-hydroxytryptamine in the dorsal raphe and substantia nigra reticulata of the rat brain.
  • Discriminative stimulus properties of cocaine: enhancement by monoamine reuptake blockers.
  • Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines.
  • 5HT1A receptor antagonists enhance the functional activity of fluoxetine in a mouse model of feeding.
  • Chromatographic analysis (TLC) of fluoxetine, doxepine, imipramine and opipramol in human plasma.
  • Pharmacological and autoradiographical characterization of serotonin transporter-like activity in sporocysts of the human blood fluke, Schistosoma mansoni.
  • Quantification of fluoxetine and norfluoxetine serum levels by reversed-phase high-performance liquid chromatography with ultraviolet detection.
  • Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine.
  • Effect of quinine on autoreceptor-regulated serotonin release in the rat hippocampus.
  • An in vitro evaluation of fluoxetine adsorption by activated charcoal and desorption upon addition of polyethylene glycol-electrolyte lavage solution.
  • Fluoxetine: relations between plasma concentration and therapeutic effects in 32 patients with major depression and treated with 20 mg/day
  • Which patients receive antidepressants? A 'real world' telephone study.
  • Hyponatraemia associated with the use of selective serotonin re-uptake inhibitors.
  • Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.
  • Effectiveness of fluoxetine (portal) in atypical depressions
  • Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenfluramine-induced head-twitch response in mice.
  • Black and white patients response to antidepressant treatment for major depression.
  • Modulation of external pancreatic secretion by endogenous norepinephrine: study with a norepinephrine uptake blocker in the rat.
  • Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women.
  • Fluoxetine and sertraline dosages in major depression.
  • Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder.
  • Selective serotonin reuptake inhibitors may enhance responses to noxious stimulation.
  • Voltammetric studies on mechanisms of dopamine efflux in the presence of substrates and cocaine from cells expressing human norepinephrine transporter.
  • Drug-nutrient interactions: inhibition of amino acid intestinal absorption by fluoxetine.
  • Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by (35)S-GTP gamma S autoradiography.
  • Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.
  • Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents.
  • Effects of fluoxetine on wild and mutant neuronal alpha 7 nicotinic receptors.
  • Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
  • Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs.
  • Modulation of delta9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat.
  • Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment.
  • Responding for rewarding brain stimulation: cocaine and isradipine plus naltrexone.
  • Interaction between sumatriptan and selective serotonin uptake inhibitors
  • Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus.
  • 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors.
  • Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability.
  • Effect of antidepressants on intracellular Ca++ mobilization in human frontal cortex.
  • Subchronic administration of fluoxetine impairs estrous behavior in intact female rats.
  • The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells.
  • Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors.
  • Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies.
  • Excitatory amino acids and serotonin uptake blockers reveal two physiologically distinct serotonin systems in the retina of the skate, Raja erinacea.
  • Residual symptoms in depressed patients who respond acutely to fluoxetine.
  • Fluoxetine action on murine T-lymphocyte proliferation: participation of PKC activation and calcium mobilisation.
  • Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat.
  • Role of central 5-HT(2) receptors in fluoxetine-induced decreases in T lymphocyte activity.
  • Fluoxetine action upon human T lymphocyte proliferation.
  • Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins.
  • Prior treatment received by patients with bulimia nervosa.
  • Classification of observational data with artificial neural networks versus discriminant analysis in pharmacoepidemiological studies--can outcome of fluoxetine treatment be predicted?
  • Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder.
  • Differential effect of polyherbal, antiobesity preparation, OB-200G in male and female mice and monosodium glutamate-treated rats.
  • Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
  • Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
  • Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine.
  • Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice.
  • Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways.
  • Effect of brain serotoninergic stimulation on sodium appetite of euthyroid and hypothyroid rats.
  • Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression.
  • Use of complementary therapies by women attending a specialist premenstrual syndrome clinic.
  • In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine.
  • Role of proline residues in the expression and function of the human noradrenaline transporter.
  • Effects of methamphetamine on responsiveness to conditioned fear stress
  • 5-HT receptor ligands differentially affect operant oral self-administration of ethanol in the rat.
  • Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze.
  • Effect of prenatal diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced aggression in rats.
  • Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life.
  • Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration.
  • Role of protein kinase C and cAMP in fluoxetine effects on human T-cell proliferation.
  • Influence of fluoxetine and litoxetine on 5-HT4 receptor-mediated relaxation in the rat isolated oesophagus.
  • Pindolol potentiates the effect of fluoxetine on hippocampal seizures in rats.
  • Ionic interactions in the Drosophila serotonin transporter identify it as a serotonin channel.
  • The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions.
  • Effect of sumatriptan on external pancreatic secretion and its interaction with endogenous norepinephrine in the rat.
  • Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells.
  • Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats.
  • Proofs of efficacy
  • Utilizing capillary gas chromatography mass spectrometry to determine 4-benzotrifluoride t-butyl ether as a reaction by-product in fluoxetine synthesized using potassium t-butoxide as base.
  • cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs.
  • Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents.
  • Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress.
  • Chronic, but not acute, clomipramine or fluoxetine treatment reduces the spontaneous firing rate in the mesoaccumbens neurons of the rat.
  • Subsyndromal depressive semiology in severe alcoholism
  • Fluoxetine's effects on cognitive performance in patients with traumatic brain injury.
  • Excretion of paroxetine into breast milk.
  • Fluoxetine inhibits K(+) transport pathways (K(+) efflux, Na(+)-K(+)-2Cl(-) cotransport, and Na(+) pump) underlying volume regulation in corneal endothelial cells.
  • Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3.
  • Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo.
  • Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.
  • Rx drugs
  • Uptake of 1-methyl-4-phenylpyridinium (MPP+) by the JAR human placental choriocarcinoma cell line: comparison with 5-hydroxytryptamine.
  • Influence of housing conditions on the effects of serotonergic drugs on feeding behavior in non-deprived rats.
  • Fluoxetine efficacy in menopausal women with and without estrogen replacement.
  • Difference in the in vivo influence of serotonin1A autoreceptors on serotonin release in prefrontal cortex and dorsal hippocampus of the same rat treated with fluoxetine.
  • Comparison of the efficacy of traditional antidepressive agents and the new generation of antidepressives in the treatment of depressive disorders
  • The combined effect of psychotherapy and fluoxetine on obesity
  • Fluoxetine (FX) efficacy in the treatment of cocaine dependence methadone maintenance patients. Interaction with plasma levels
  • Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study.
  • The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat.
  • Trazodone increases extracellular serotonin levels in the frontal cortex of rats.
  • Fluoxetine modulates norepinephrine contractile effect on rat vas deferens.
  • Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment
  • Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.
  • Regional brain distribution of noradrenaline uptake sites, and of alpha1-alpha2- and beta-adrenergic receptors in PCD mutant mice: a quantitative autoradiographic study.
  • Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice.
  • Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats.
  • Electrophysiological effects of fluoxetine in mammalian cardiac tissues.
  • Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine.
  • Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus.
  • Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats.
  • Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors.
  • Nutritional management of anorexic patients with and without fluoxetine: 1-year follow-up.
  • Effects of fluoxetine on the 5-HT1A receptor and recovery of cognitive function after traumatic brain injury in rats.
  • Spectrophotometric determination of fluoxetine and sertraline using chloranil, 2, 3 dichloro-5, 6 dicyano benzoquinone and iodine.
  • Potentiation of opioid-induced conditioned place preference by the selective serotonin reuptake inhibitor fluoxetine.
  • Effects of antidepressants in adrenergic neurotransmission of human vas deferens.
  • Differential effects of beta-carbolines and antidepressants on rat exploratory activity in the elevated zero-maze.
  • Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat.
  • Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies.
  • Inhibitory effect of serotonergic drugs on contractile response of the rat vas deferens to electrical nerve stimulation: in vivo study.
  • Fluoxetine prevents PCP- and MK801-induced HSP70 expression in injured limbic cortical neurons of rats.
  • Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications.
  • Leukocyte subsets in treatment-resistant major depression.
  • Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents.
  • Newer antidepressants: a comparison of tolerability in general practice.
  • Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle Ca2+i.
  • The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572.
  • Effect of fluoxetine on intraocular pressure in the rabbit.
  • Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine(1A) receptors in hypothalamus.
  • Multiple ejaculations and chronic fluoxetine: effects on male rat copulatory behavior.
  • C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway.
  • Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus.
  • Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study.
  • Repeated administration of fluoxetine, desipramine and tranylcypromine increases dopamine D2-like but not D1-like receptor function in the rat.
  • Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.
  • Do antidepressants affect motivation in conditioned place preference?
  • Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebo-controlled trials.
  • 5-HT4 receptors do not mediate the antidepressant-like behavioral effects of fluoxetine in a modified forced swim test.
  • Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.
  • Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis.
  • Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice.
  • Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells.
  • Fluoxetine-induced Ca2+ signals in Madin-Darby canine kidney cells.
  • Disorder of eating behavior and comorbid syndromes in obesity and methods of their correction
  • Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study
  • Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
  • Rapid desensitization of 5-HT(1A) receptors in Fawn-Hooded rats after chronic fluoxetine treatment.
  • Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs.
  • Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors.
  • Desipramine and fluoxetine antagonized 5,7-dihydroxytryptamine-induced lesion on rat hippocampal and cortical neurons.
  • The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability?
  • Antibodies against human putamen in adolescents with anorexia nervosa.
  • Rx drugs
  • Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters.
  • Magnetization transfer of fluoxetine in the human brain using fluorine magnetic resonance spectroscopy.
  • Antidepressant effect of water decoction of Rhizoma acori tatarinowii in the behavioural despair animal models of depression
  • Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
  • Chronic treatment of C6 glioma cells with antidepressant drugs results in a redistribution of Gsalpha.
  • NMR studies on three optical active drug molecules.
  • Comparison of peripheral inhibitory effects of clomipramine with selective serotonin re-uptake inhibitors on contraction of vas deferens: in vitro and in vivo studies.
  • Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
  • Effect of fluoxetine on intracellular Ca2+ levels in bladder female transitional carcinoma (BFTC) cells.
  • Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus.
  • Potentiation of kappa-opioid receptor agonist-induced analgesia and hypothermia by fluoxetine.
  • Mood disorders in children and adolescents: psychopharmacological treatment.
  • Inhibition of the serotonin 5-HT3 receptor by nicotine, cocaine, and fluoxetine investigated by rapid chemical kinetic techniques.
  • Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.
  • Simultaneous determination of fluoxetine and its metabolite p-trifluoromethylphenol in human liver microsomes using a gas chromatographic-electron-capture detection procedure.
  • Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment.
  • SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.
  • Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine.
  • Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics.
  • Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice.
  • Effect of repeated treatment with tianeptine and fluoxetine on the central alpha(1)-adrenergic system.
  • The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
  • Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
  • Rx drugs
  • Balance control and posture in anxious mice improved by SSRI treatment.
  • Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice.
  • Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity.
  • On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor.
  • Effects of acute and chronic fluoxetine treatments on restraint stress-induced Fos expression.
  • Patient perspectives on once-weekly fluoxetine.
  • Biosynthesis of the neurosteroid 3 alpha-hydroxy-4-pregnen-20-one (3 alpha hp), a specific inhibitor of FSH release.
  • Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats.
  • Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
  • Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
  • Fetal behavioural state changes following maternal fluoxetine infusion in sheep.
  • Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes.
  • Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
  • Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology.
  • Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction?
  • Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model.
  • Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus.
  • Functional significance of a highly conserved glutamate residue of the human noradrenaline transporter.
  • Rx drugs
  • Differential acute effects of fluoxetine on frontal and auditory cortex networks in vitro.
  • Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.
  • Rapid methods for determination of fluoxetine in pharmaceutical formulations.
  • Repeated treatment with antidepressants differentially alters 5-HT1A agonist-stimulated 35SGTP gamma S binding in rat brain regions.
  • Sympathetic activation by fenfluramine depletes brown adipose tissue norepinephrine content in rats.
  • A typological model for estimation of drug and placebo effects in depression.
  • Behavioral and neurochemical effects of 5-(4-4-(5-Cyano-3-indolyl)-butyl)-butyl-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
  • Rx drugs
  • Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice.
  • Personality disorders and depression.
  • Enhanced amphetamine-mediated dopamine release develops in PC12 cells after repeated amphetamine treatment.
  • Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine
  • Reduced basal release of serotonin from the ventrobasal thalamus of the rat in a model of neuropathic pain.
  • Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
  • Rx drugs
  • Fluoxetine differentially suppresses sucrose solution consumption in free-fed and food-deprived rats--reversal by amantadine.
  • Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions.
  • Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study.
  • Protein kinase C and the sub-sensitivity and sub-reactivity of the diabetic rat prostate gland to noradrenaline.
  • S-18Ffluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats.
  • Rx drugs
  • Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus.
  • Mechanism of nicotine-evoked release of 3H-noradrenaline in human cerebral cortex slices.
  • Calcium channel blocking activity of thioridazine, clomipramine and fluoxetine in isolated rat vas deferens: a relative potency measurement study.
  • Rx drugs
  • Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure.
  • Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project.
  • R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study.
  • Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders.
  • Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects.
  • Effect of isolation rearing on pre- and post-synaptic serotonergic function in the rat dorsal hippocampus.
  • Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors.
  • Rx drugs
  • Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study.
  • Chronic cocaine self-administration upregulates the norepinephrine transporter and alters functional activity in the bed nucleus of the stria terminalis of the rhesus monkey.
  • Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function.
  • Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain.
  • A preliminary study of the effect of fluoxetine treatment on the 2:16-alpha-hydroxyestrone ratio in young women.
  • Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain.
  • Fluoxetine increases GABA(A) receptor activity through a novel modulatory site.
  • Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats.
  • Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
  • Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.
  • Uptake of serotonin by adult rat corpus callosum is partially reduced by common antidepressants.
  • Rx drugs
  • Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats.
  • Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice.
  • Control of endogenous norepinephrine release in the hypothalamus of male rats changes over adolescent development.
  • Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935.
  • Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac).
  • Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
  • Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
  • Juvenile obsessive-compulsive disorder.
  • EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.
  • Fluoxetine selectively alters 5-hydroxytryptamine1A and gamma-aminobutyric acidB receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells.
  • Depressive retardation and treatment with fluoxetine: assessment of the motor component.
  • Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine.
  • Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters.
  • Single pump column switching technique employing a flow gradient and wavelength programmed fluorescence for simultaneous monitoring of serotonin, fluoxetine and norfluoxetine in rat brain microdialysate.
  • GAP-43 phosphorylation by PKC in rat cerebrocortical synaptosomes: effect of antidepressants.
  • MDMA induced dopamine release in vivo: role of endogenous serotonin.
  • Studies on modulation of feeding behavior by atypical antipsychotics in female mice.
  • A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine
  • Influence of fluoxetine and p-chloroamphetamine on the somatostatin receptor-adenylyl cyclase system in the rat frontoparietal cortex.
  • Benzodiazepine withdrawal facilitates the subsequent onset of escape failures and anhedonia: influence of different antidepressant drugs.
  • Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats.
  • Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
  • Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: a comparison with fluoxetine.
  • Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter.
  • Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
  • Fluoxetine-induced plasticity in the rodent visual system.
  • Greater effects of fluoxetine and its combination with (-)-pindolol in elevating hypothalamic serotonin in rats during dark hours.
  • Lipopolysaccharide-mediated immobility in mice: reversal by cyclooxygenase enzyme inhibitors.







    DreamPharm: Herbal and Nutritional supplements online || Hair Million herbal formula for hair loss and hair growth || Insurance plans and information || Insurance policies for all purposes || Antibiotics and prescription medications online literature ||